MINNEAPOLIS--(BUSINESS WIRE)--Donaldson Company, Inc. (NYSE: DCI) (Donaldson or the Company), a leading worldwide provider of innovative filtration products and solutions, today announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A. (Medica).

明尼阿波利斯--（商业新闻短讯）--唐纳森公司（纽约证券交易所：DCI）（唐纳森或该公司）是创新过滤产品和解决方案的全球领先供应商，今天宣布，它已签署最终协议，允许该公司购买Medica S.p.a.（Medica）49%的股份。

Medica is a leader in hollow fiber membrane filtration technology for medical device applications and water purification. Headquartered in Medolla, Italy, the Company has over 700 employees globally and generated €80 million of revenue in calendar 2023..

Medica是用于医疗器械应用和水净化的中空纤维膜过滤技术的领导者。该公司总部位于意大利梅多拉，在全球拥有700多名员工，2023年实现收入8000万欧元。。

Founded in 1985, Medica’s innovative hollow fiber membrane filtration products are used for blood purification in numerous applications including dialysis, continuous renal replacement therapies (CRRT), and therapeutic apheresis. The Company’s products and technologies are also used in the microbiological purification of water, as well as automation solutions for disposable medical device manufacturing..

Medica公司成立于1985年，其创新的中空纤维膜过滤产品被用于血液净化的许多应用，包括透析、连续肾脏替代疗法（CRRT）和治疗性单采血液。该公司的产品和技术还用于水的微生物净化，以及一次性医疗器械制造的自动化解决方案。。

“Hollow fiber membrane filtration is a fundamental filtration technology and Medica’s proprietary technology and expertise, along with their world-class manufacturing capabilities has enabled delivery of innovative, high-margin products to customers in several markets,” said Tod Carpenter, chairman, president and chief executive officer of Donaldson..

唐纳森董事长、总裁兼首席执行官托德·卡彭特（TodCarpenter）表示：“中空纤维膜过滤是一种基本的过滤技术，Medica的专有技术和专业知识以及世界一流的制造能力使其能够向多个市场的客户提供创新的高利润产品。”。。

The acquisition is subject, inter alia, to the positive outcome of the voluntary totalitarian tender offer on the ordinary shares of Medica, which MavenDanc S.r.l., an Italian company entirely owned by Donaldson, formally announced to the market on the date hereof by way of publication of the communication required by article 102, paragraph 1, of Legislative Decree n.

除其他外，此次收购取决于对Medica普通股的自愿极权收购要约的积极结果，这是Donaldson全资拥有的意大利公司MavenDanc S.r.l.于本协议签署之日正式向市场宣布的，发布了第n号法令第102条第1款所要求的通信。

58 of 24 February 1998 (as amended from time to time) (the '102 Notice'). Copy of the 102 Notice is available to the public on Medica website at www.medica-spa.com. Upon positive outcome of the tender offer, Donaldson will acquire a 49% stake of Medica with the option to acquire the remaining 51% stake in the future.

1998年2月24日第58号（不时修订）（“102公告”）。102公告的副本可在Medica网站www.Medica-spa.com上向公众提供。一旦收购要约取得积极结果，唐纳森将收购Medica 49%的股份，并有权在未来收购其余51%的股份。

Completion of the transaction is expected by the third quarter of calendar 2024. Upon closing, the ratable share of Medica’s earnings would be included as a part of the Donaldson Life Sciences segment..

交易预计在2024年第三季度完成。交割后，Medica收入中的按比例分配份额将作为唐纳森生命科学分部的一部分。。

Statements in this release regarding future events and expectations, such as forecasts, plans, trends and projections relating to Donaldson’s business and financial performance, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are identified by words or phrases such as “will likely result,” “are expected to,” “will continue,” “will allow,” “estimate,” “project,” “believe,” “expect,” “anticipate,” “forecast,” “plan” and similar expressions.

本新闻稿中有关未来事件和预期的声明，如与唐纳森的业务和财务业绩有关的预测、计划、趋势和预测，是1995年《私人证券诉讼改革法案》含义范围内的前瞻性声明，并由“可能会产生”、“预计会”、“将继续”、“将允许”、“估计”、“项目”、“相信”、“预期”、“预计”、“预测”、“计划”等词语或短语标识。

These forward-looking statements speak only as of the date such statements are made and are subject to risks and uncertainties that could affect Donaldson’s performance and could cause Donaldson’s actual results for future periods to differ materially from any opinions or statements expressed. These factors include, but are not limited to, challenges in global operations; impacts of global economic, industrial and political conditions on product demand; impacts from unexpected events, including natural disasters; effects of unavailable raw materials or material cost inflation; inability to attract and retain qualified personnel; inability to meet customer demand; inability to maintain competitive advantages; threats from disruptive technologies; effects of highly competitive markets with pricing pressure; exposure to customer concentration in certain cyclical industries; inability to manage productivity improvements; inability to achieve commitments to ESG; results of execution of any acquisition, divestiture and other strategic transactions; vulnerabilities associated with information technology systems and security; inability to protect and enforce intellectual property rights; costs associated with governmental laws and regulations; impacts of foreign currency fluctuation.

这些前瞻性声明仅在做出此类声明之日起生效，并受到可能影响唐纳森业绩的风险和不确定性的影响，并可能导致唐纳森未来时期的实际业绩与所表达的任何意见或声明存在重大差异。这些因素包括但不限于全球运营中的挑战；全球经济、工业和政治条件对产品需求的影响；包括自然灾害在内的突发事件的影响；原材料不可用或材料成本上涨的影响；无法吸引和留住合格人员；无法满足客户需求；无法保持竞争优势；破坏性技术的威胁；具有定价压力的高度竞争市场的影响；暴露于某些周期性行业的客户集中；无法管理生产力改进；无法实现对ESG的承诺；任何收购、资产剥离和其他战略交易的执行结果；与信息技术系统和安全相关的漏洞；无法保护和执行知识产权；与政府法律法规相关的费用；外汇波动的影响。

About Donaldson Company, Inc.

关于唐纳森公司。

Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Diverse, skilled employees at over 140 locations on six continents partner with customers—from small business owners to R&D organizations and the world’s biggest OEM brands.

唐纳森（纽约证券交易所代码：DCI）成立于1915年，是以技术为主导的过滤产品和解决方案的全球领导者，服务于广泛的行业和先进市场。来自六大洲140多个地点的多样化、熟练的员工与客户合作，从小企业主到研发机构，再到世界最大的OEM品牌。

Donaldson solves complex filtration challenges through three primary segments: Mobile Solutions, Industrial Solutions and Life Sciences. Additional information is available at www.Donaldson.com..

唐纳森通过三个主要部分解决了复杂的过滤挑战：移动解决方案、工业解决方案和生命科学。更多信息请访问www.Donaldson.com。。

About Medica S.p.A

关于Medica S.p.A

Medica Group has been operating since 1985 with its headquarters in the biomedical district of Mirandola, Italy. Development of innovative products for blood purification has been the Group’s core business leveraging R&D strength in hollow fiber membrane technology, as well as the design and development of electromedical equipment and related disposables.

Medica集团自1985年开始运营，总部位于意大利米兰多拉生物医学区。利用中空纤维膜技术的研发实力，以及电子医疗设备和相关一次性用品的设计和开发，开发用于血液净化的创新产品一直是该集团的核心业务。

Today the Group is vertically integrated, has multiple manufacturing locations, and sales in over 60 countries successfully competing in several markets, namely: 1) Medical (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification), 2) Microbiological purification of water, and 3) Industrial automation for the biomedical sector.

如今，该集团已实现垂直整合，拥有多个生产基地，并在60多个国家成功销售，在多个市场竞争，即：1）医疗（透析，CRRT，ECCO2，单采，DFPP，CHF，HIPEC，移植前器官灌注，生物再生医学，胃肠学，尿动力学，氧气加湿），2）水的微生物净化，以及3）生物医学行业的工业自动化。

Additional information is available at www.medica-spa.com..

更多信息请访问www.medica-spa.com。。